MedPath

Memorial Sloan Kettering Cancer Center

Memorial Sloan Kettering Cancer Center logo
🇺🇸United States
Ownership
Private
Established
1884-01-01
Employees
10K
Market Cap
-
Website
http://www.mskcc.org

Application of High Resolution Diffusion-weighted MR Imaging Pulse Sequence in Head and Neck, and Prostate Cancers

Completed
Conditions
Prostate Cancer
Head and Neck Cancer
Interventions
Other: MRI scanner with sequence
First Posted Date
2012-02-20
Last Posted Date
2017-05-08
Lead Sponsor
Memorial Sloan Kettering Cancer Center
Target Recruit Count
10
Registration Number
NCT01535898
Locations
🇺🇸

Memorial Sloan Kettering Cancer Center, New York, New York, United States

Doctor-Patient Communication About Colorectal Cancer Screening

Completed
Conditions
Colorectal Cancer Screening
Interventions
Behavioral: surveys
First Posted Date
2012-02-17
Last Posted Date
2020-01-02
Lead Sponsor
Memorial Sloan Kettering Cancer Center
Target Recruit Count
76
Registration Number
NCT01534923
Locations
🇺🇸

Albert Einstein College of Medicine, Bronx, New York, United States

🇺🇸

Hhc, Gun Hill and Tremont, Bronx, New York, United States

MRI and Diffusion Imaging of Eloquent Brain Areas to Optimize Brain Tumor Resection Planning

Not Applicable
Completed
Conditions
Brain Cancer
Interventions
Procedure: preoperative fMRI. DTI and DSI with tractography
First Posted Date
2012-02-16
Last Posted Date
2023-06-09
Lead Sponsor
Memorial Sloan Kettering Cancer Center
Target Recruit Count
145
Registration Number
NCT01534104
Locations
🇺🇸

Memorial Sloan Kettering Cancer Center, New York, New York, United States

Tobacco Dependence in Breast Cancer Patients Trial of Varenicline (Chantix)

Terminated
Conditions
Breast Cancer
Tobacco Dependence
Interventions
Drug: placebo
First Posted Date
2012-02-14
Last Posted Date
2015-12-23
Lead Sponsor
Memorial Sloan Kettering Cancer Center
Target Recruit Count
7
Registration Number
NCT01532232
Locations
🇺🇸

Memorial Sloan-Kettering Cancer Center, New York, New York, United States

Afatinib and Paclitaxel in Patients With Advanced HER2-Positive Trastuzumab-Refractory Advanced Esophagogastric Cancer

Phase 2
Completed
Conditions
Esophageal Cancer
Gastric Cancer
Interventions
First Posted Date
2012-02-01
Last Posted Date
2023-11-01
Lead Sponsor
Memorial Sloan Kettering Cancer Center
Target Recruit Count
42
Registration Number
NCT01522768
Locations
🇺🇸

Memorial Sloan Kettering Rockville Centre, Rockville Centre, New York, United States

🇺🇸

Memorial Sloan Kettering Cancer Center, New York, New York, United States

🇺🇸

Massachusetts General Hospital Cancer Center, Boston, Massachusetts, United States

and more 6 locations

Attention and Interpretation Modification (AIM) for Fear of Cancer Recurrence: An Intervention Development Study

Active, not recruiting
Conditions
Breast Cancer
Rare Cancer
Interventions
Behavioral: AIM materials and assessments
First Posted Date
2012-01-25
Last Posted Date
2025-02-04
Lead Sponsor
Memorial Sloan Kettering Cancer Center
Target Recruit Count
252
Registration Number
NCT01517945
Locations
🇺🇸

Memorial Sloan Kettering Cancer Center, New York, New York, United States

Brentuximab Vedotin (SGN-35) in Transplant Eligible Patients With Relapsed or Refractory Hodgkin Lymphoma

Phase 2
Completed
Conditions
Hodgkin's Lymphoma
Interventions
First Posted Date
2012-01-11
Last Posted Date
2025-01-23
Lead Sponsor
Memorial Sloan Kettering Cancer Center
Target Recruit Count
66
Registration Number
NCT01508312
Locations
🇺🇸

Memorial Sloan Kettering Cancer Center, New York, New York, United States

International Travel Patterns and Health Preparations of Hematopoietic Stem Cell Transplant Recipients at Memorial Sloan-Kettering Cancer Center

Completed
Conditions
Hematopoietic Stem Cell Transplant
Interventions
Behavioral: questionnaire
First Posted Date
2012-01-05
Last Posted Date
2013-07-12
Lead Sponsor
Memorial Sloan Kettering Cancer Center
Target Recruit Count
519
Registration Number
NCT01504152
Locations
🇺🇸

Memorial Sloan-Kettering Cancer Center, New York, New York, United States

Pre-Operative, Single-Dose Ipilimumab and/or Cryoablation in Early Stage/Resectable Breast Cancer

Phase 1
Completed
Conditions
Invasive Adenocarcinoma of the Breast
Breast Cancer
Interventions
Biological: Ipilimumab
Procedure: Cryoablation
First Posted Date
2011-12-30
Last Posted Date
2016-01-05
Lead Sponsor
Memorial Sloan Kettering Cancer Center
Target Recruit Count
19
Registration Number
NCT01502592
Locations
🇺🇸

Memorial Sloan Kettering Cancer Center, New York, New York, United States

Examinations of Tissue From Ablated Malignant Liver Metastases as Predictors of Outcome

Not Applicable
Active, not recruiting
Conditions
Liver Cancer
Interventions
Other: CT guided percutaneous ablation
First Posted Date
2011-12-19
Last Posted Date
2025-04-17
Lead Sponsor
Memorial Sloan Kettering Cancer Center
Target Recruit Count
150
Registration Number
NCT01494324
Locations
🇺🇸

Memorial Sloan Kettering Cancer Center, New York, New York, United States

© Copyright 2025. All Rights Reserved by MedPath